SCHEMBL5636451

SCHEMBL5636451

Clc1ccc(-c2cc3c4c(c2)[C@@H]2CNCC[C@@H]2N4CCCO3)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 8/20 0.51
HTR2A P28223 5/20 0.43
HTR2B P41595 4/20 0.43
MAPK1 P28482 2/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
KMT2A Q03164 1/20 0.31
MGLL Q99685 1/20 0.30
AHR P35869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636639 0.94 HTR2C (0.48) HTR2CHTR2AHTR2BMAPK1ALDH1A1
SCHEMBL5636363 0.92 HTR2C (0.42) HTR2CHTR2AHTR2B
SCHEMBL5636424 0.91 HTR2C (0.47) HTR2CHTR2AHTR2B
SCHEMBL5636401 0.89 HTR2C (0.45) HTR2CHTR2AHTR2B
SCHEMBL5636687 0.88 HTR2C (0.56) HTR2CHTR2AHTR2B
SCHEMBL5638182 0.88 HTR2C (0.48) HTR2CHTR2AHTR2BMAPK1ALDH1A1
SCHEMBL5636965 0.87 HTR2C (0.42) HTR2CHTR2AHTR2BMAPK1ALDH1A1
SCHEMBL5636217 0.86 HTR2C (0.40) HTR2CHTR2AHTR2B
SCHEMBL5636282 0.86 HTR2C (0.46) HTR2CHTR2AHTR2B
SCHEMBL5638526 0.85 HTR2C (0.44) HTR2CHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed